CGEN Stock — Compugen

Compugen (CGEN)

Updated October 16, 2026.

CGEN is a Stock. Total return is -82.4% over the past 26.2 years, 807.2 points behind SPY at 724.8%.

Compugen is a clinical-stage therapeutic company developing immuno-oncology antibody treatments for solid tumors and other cancers, with programs including COM701 (anti-PVRIG), COM902 (anti-TIGIT), Bapotulimab (anti-ILDR2), and Rilvegostomig (anti-PD-1/TIGIT bispecific) across Phase 1 and Phase 3 clinical trials, along with collaboration and licensing agreements with Bristol-Myers Squibb, AstraZeneca, and Gilead Sciences. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage biopharmaceutical development with no current income component.

CGEN performance versus SPY

Price and return data through 2026-10-16.

Total return is -82.4% over the past 26.2 years, 807.2 points behind SPY at 724.8%. Over the past year its total return — price change plus distributions reinvested — is 0.5%. Its deepest 1-year drawdown was 36.8%.

CGEN key facts

Asset type

Stock

Asset class

Equity

Inception date

08/11/2000

Distribution frequency

None

Last close

$1.96 (as of 2026-10-16)

Market cap

$185,659,326

Average volume

169433.0

Beta

2.787

Payout ratio

0.0%

P/E ratio

5.16

Forward P/E

12.3609

EPS

$0.38

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CGEN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 36.8%.

Who may consider CGEN — and who may not

It is a weaker fit for investors who need monthly cash flow (CGEN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CGEN

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions